PDF herunterladen
Aktuelle Dermatologie 2008; 34(12): 475-481
DOI: 10.1055/s-2008-1077766
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Kutane Lymphome 2008[*]

Cutaneous Lymphomas 2008R.  Stadler1
  • 1Dermatologie, Johannes Wesling Klinikum Minden
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
28. November 2008 (online)

Auch verfügbar auf
  Lizenzen und Reprints
Preview

Zusammenfassung

Kutane Lymphome werden mit dem Jahr 2008 weltweit einheitlich von Dermatologen, Onkologen und Pathologen klassifiziert. Inzwischen werden zwei Varianten von subkutanen Pannikulitis-ähnlichen T-Zell-Lymphomen mit unterschiedlicher Überlebensprognose unterschieden. Eine neue Entität stellt das blastische plasmazytoide dendritische T-Zell-Lymphom dar. Kutane B-Zell-Lymphome werden durch neue molekulare Marker, z. B. MUM1, genauer klassifiziert. Die aktuellen Therapiekonzepte kutaner Lymphome wurden kürzlich in der Deutschen Kurzleitlinie im Journal der Deutschen Dermatologischen Gesellschaft veröffentlicht.

Abstract

The year 2008 is characterized by an unified worldwide classification for dermatologists, oncologists and pathologists. Meanwhile, two variants of cutaneous panniculitis-like T-cell lymphomas are distinguishable with different prognosis of survival. Blastic plasmacytoid dendritic T-cell lymphoma can be regarded as a new entity. Cutaneous B-cell lymphoma are characterized by new molecular markers as MUM1. The current therapy concept of cutaneous lymphoma, the new treatment guidelines, are published in the Journal of the German Dermatological Society.

1 Nach einem Vortrag gehalten anlässlich des Symposions „Moderne Aspekte der Dermatoonkologie” organisiert vom Tumorzentrum und der Klinik für Dermatologie, Venerologie und Allergologie – Immunologisches Zentrum, Städtisches Klinikum Dessau, März 2007.

Literatur

  • 1 Assaf C, Gellrich S, Whittaker S. CD56-positive haematological neoplasm of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer.  J Clin Pathol. 2007;  60 981-989
    PubMedSuche in Google Scholar
  • 2 Bunn Jr P A, Hoffmann S J, Norris D, Golitz L E, Aeling J L. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).  Ann Intern Med. 1994;  121 592-602
    PubMedSuche in Google Scholar
  • 3 Dummer R. Emerging drugs in cutaneous T-cell lymphomas.  Expert Opin. 2005;  10 381-392
    CrossrefPubMedSuche in Google Scholar
  • 4 Dummer R, Assaf C, Bagot M, Gniadecki R, Hauschild A, Knobler R, Ranki A, Stadler R, Whittaker S. Maintenance therapy in cutaneous T-cell lymphoma: Who, when, what?.  Eur J Cancer. 2007;  43 2321-2329
    CrossrefPubMedSuche in Google Scholar
  • 5 Duvic M, Foss F M. Mycosis fungoides: pathophysiology and emerging therapies.  Semin Oncol. 2007;  34 (Suppl 5) S21-S28
    PubMedSuche in Google Scholar
  • 6 Duvic M, Hymes K, Heald P, Breneman D, Martin A G, Myskowski P, Crowley C, Yocum R C. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational Phase II-III trial results.  J Clin Oncol. 2001;  19 2456-2471
    PubMedSuche in Google Scholar
  • 7 Faderl S, Coutre S, Byrd J C, Dearden C, Denes A, Dyer M J, Gregory S A, Gribben J G, Hillmen P, Keating M, Rosen S, Venugopal P, Rai K. The evolving role of alemtuzumab in management of patients with CLL.  Leukemia. 2005;  19 2147-2152
    CrossrefPubMedSuche in Google Scholar
  • 8 Farol L T, Hymes K B. Bexarotene: a clinical review.  Expert Rev Anticancer Ther. 2004;  4 180-188
    CrossrefPubMedSuche in Google Scholar
  • 9 Foss F. Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches.  Leuk Lymph. 2003;  44 (Suppl 3) S55-S61
    CrossrefPubMedSuche in Google Scholar
  • 10 Gandhi V, Balakrishnan K. Pharmacology and mechanism of action for forodesine, a T-cell targeted agent.  Semin Oncol. 2007;  34 (Suppl 5) S8-S12
    CrossrefPubMedSuche in Google Scholar
  • 11 Jacob M C, Chaperot C, Smossuz P. et al . CD4-positiv, CD56-positive lineage negative malignancies: a new entity developed from malignant early plasmocytoid dendritic cells.  Haematologica. 2003;  88 941-955
    PubMedSuche in Google Scholar
  • 12 Jacobs S A, Foon K A. Monoclonal antibody therapy of leukemias and lymphomas.  Expert Opin Biol Ther. 2005;  5 1225-1243
    CrossrefPubMedSuche in Google Scholar
  • 13 Jaffe E S, Harris N L, Stein H, Vardiman J W. (eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. Lyon; IARC Press 2001
    Suche in Google Scholar
  • 14 Johnstone R W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.  Nat Rev Drug Discov. 2002;  1 287-299
    CrossrefPubMedSuche in Google Scholar
  • 15 Kim E J, Hess S, Richardson S K, Newton S, Showe L C, Benoit B M, Ubriani R, Vittorio C, Junkins-Hopkins J M, Wysocka M, Rook A H. Immunopathogenesis and therapy of cutaneous T-cell lymphoma.  J Clin Invest. 2005;  115 798-812
    PubMedSuche in Google Scholar
  • 16 Kim Y H, Willemze R, Pimpinelli N. et al . TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organisaion of Research and Treatment of Cancer (EORTC).  Blood. 2007;  110 479-484
    CrossrefPubMedSuche in Google Scholar
  • 17 Knobler R, Girardi M. Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphomas.  Ann NY Acad Sci. 2001;  94 123-138
    PubMedSuche in Google Scholar
  • 18 Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.  J Clin Oncol. 2001;  19 376-388
    PubMedSuche in Google Scholar
  • 19 Olsen E A, Kim Y H, Kuzel T M, Pacheco T R, Foss F M, Parker S, Frankel S R, Chen C, Ricker J L, Arduino J M, Duvic M. Phase Iib multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.  J Clin Oncol. 2007;  26 332-334
    PubMedSuche in Google Scholar
  • 20 Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Berengo M G, Sterry W, Laroche L, Trautinger F, Whittaker S. ISCL/EORTC . Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organisaion of Research and Treatment of Cancer (EORTC).  Blood. 2007;  110 1713-1722
    CrossrefPubMedSuche in Google Scholar
  • 21 Piekarz R L, Robey R, Sandor V, Bakke S, Wilson W H, Dahmoush L, Kingma D M, Turner M L, Altemus R, Bates S E. Inhibitor of histone deacetylation, depsipeptide (FR901288), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.  Blood. 2001;  98 2865-2868
    CrossrefPubMedSuche in Google Scholar
  • 22 Querfeld C, Rosen S T, Kuzel T M, Kirbs K A, Roenigk H H, Prinz B M, Guitart J. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.  Arch Dermatol. 2005;  141 305-311
    CrossrefPubMedSuche in Google Scholar
  • 23 Rupoli S, Goteri G, Pulini S, Filosa A, Tassetti A, Offidani M, Filosa G, Mozzicafreddo G, Giacchetti A, Brandozzi G, Cataldi I, Barulli S, Ranaldi R, Scortechini A R, Capretti R, Fabris G, Leoni P. Long-term experience with low-dose interferon-α and PUVA in the management of early mycosis fungoides.  Eur J Haematol. 2005;  75 136-145
    CrossrefPubMedSuche in Google Scholar
  • 24 Stadler R. Interferons in Dermatology – Present-day standard.  Dermatol Clin. 1998;  16 377-398
    PubMedSuche in Google Scholar
  • 25 Stadler R, Assaf C, Klemke C-D, Nashan D, Weichenthal M, Dummer R, Sterry W. Kurzleitlinie – Kutane Lymphome.  JDDG. 2008;  6 (Suppl. 1) S29-S35
    PubMedSuche in Google Scholar
  • 26 Stadler R, Kremer A. Kutane maligne Lymphome – Klinik, Diagnostik und Therapiestrategien. Bremen, London, Boston; UNI-MED Verlag AG 2006
    Suche in Google Scholar
  • 27 Stadler R, Kremer A. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids.  Semin Oncol. 2006;  33 (1 Suppl 3) S7-S10
    PubMedSuche in Google Scholar
  • 28 Stadler R, Otte H G, Luger T, Henz B M, Kühl P, Zwingers T, Sterry W. Prospective randomized multicenter clinical trial on the use of interferon α-2a plus acitretin versus intferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma, stages I and II.  Blood. 1998;  92 3578-3581
    PubMedSuche in Google Scholar
  • 29 Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, D’Incan M, Ranki A, Pimpinelli N, Ortiz-Romero P, Dummer R, Estrach T, Whittaker S. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome.  Eur J Cancer. 2006;  42 1014-1030
    CrossrefPubMedSuche in Google Scholar
  • 30 Urosevic M, Dummer R, Contrad C, Beyeler M, Laine E, Burg G, Gilliet M. Disease-Independent Skin Recruitment and Activation of plasmacytoid predendritic cells following imiquimod.  J Nat Cancer Inst. 2005;  15 1143-1153
    PubMedSuche in Google Scholar
  • 31 van Dognen J J, Langerak A W, Bruggemann M, Evans P A, Hummel M, Lavender F L, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, van Kriken J H, Droese J, Gonzalez D, Bastard C, White H E, Spaargaren M, Gonzalez M, Parreira A, Smith J L, Morgan G J, Kneba M, Macintyre E A. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98 – 3936.  Leukemia. 2003;  17 2257-2317
    CrossrefPubMedSuche in Google Scholar
  • 32 Vonderheid E C, Berengo M G, Burg G, Duvic M, Heald P, Laroche L, Olsen E, Pttelkow M, Russel-Jones R, Takigawa M, Willemze R. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas.  J Am Acad Dermatol. 2002;  46 95-106
    CrossrefPubMedSuche in Google Scholar
  • 33 Whittaker S J, Foss F M. Efficacy and tolerability of currently available therapies for mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.  Cancer Treat Rev. 2007;  33 146-160
    CrossrefPubMedSuche in Google Scholar
  • 34 Willemze R, Jaffe E S, Burg G, Cerrni L, Berti E, Swerdlow S H, Ralfkiaer E, Chimenti S, Diaz-Perez J L, Duncan L M, Grange F, Harris N L, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer M H, Wechsler J, Whittaker S, Meijer C JLM. WHO-EORTC classification for cutaneous lymphomas.  Blood. 2005;  105 3768-3785
    CrossrefPubMedSuche in Google Scholar
  • 35 Willemze R, Jansen P, Cerroni L, Berti E, Santucci M, Assaf C, Canninga-van Dijk M R, Carlotti A, Geerts M L, Hahtola S, Hummel M, Jeskanen L, Kempf W, Massone C, Ortiz-Romero P L, Paulli M, Petrella T, Ranki A, Peralto J L, Robson A, Senff N J, Vermeer M H, Wechsler J, Whittaker S, Meijer C J. EORTC Cutaneous Lymphoma Group . Subcutaneous panniculitis-like T-cell lymphoma: definition, classification and prognostic factors. An EORTC Cutaneous Lymphoma Group Study of 83 Cases.  Blood. 2008;  111 838-845
    CrossrefPubMedSuche in Google Scholar
  • 36 Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, Diaz-Peréz J L, Geerts M L, Goos M, Knobler R, Ralkiaer E, Santucci M, Smith N, Wechsler J, van Vloten W A, Meijer C CJLM. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of th European Organization for Research and Treatment of Cancer.  Blood. 1997;  90 354-371
    PubMedSuche in Google Scholar
  • 37 Wollina U, Dummer R, Brockmeyer N H, Konrad H, Busch J O, Kaatz M, Knopf B, Koch H J, Hauschild A. Multicenter study of pegylated liposomal docorubicin in patients with cutaneous T-cell lymphoma.  Cancer. 2003;  98 993-1001
    CrossrefPubMedSuche in Google Scholar
  • 38 Zinzani P L, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Sabattini E, Pileri S, Baccarani M. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.  J Clin Oncol. 2007;  25 4293-4297
    CrossrefPubMedSuche in Google Scholar

1 Nach einem Vortrag gehalten anlässlich des Symposions „Moderne Aspekte der Dermatoonkologie” organisiert vom Tumorzentrum und der Klinik für Dermatologie, Venerologie und Allergologie – Immunologisches Zentrum, Städtisches Klinikum Dessau, März 2007.

Prof. Dr. med. Rudolf Stadler

Dermatologie
Johannes Wesling Klinikum

Hans-Nolte-Str. 1
32429 Minden

eMail: hautklinik@klinikum-minden.de